Introduction About 30–40% of patients with pancreatic ductal adenocarcinoma (PDAC) have a locally advanced pancreatic cancer (LAPC) which is non-metastatic and limited to the pancreatic region, but unresectable due to involvement of major blood vessels.1 The recommended management in eligible patients consists of chemotherapy with 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine/nab-paclitaxel (G/NP) combinations potentially followed by chemoradiation depending on...
